Fingolimod-associated macular edema
Authors:
- 28 February 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (9) , 672-680
Abstract
Fingolimod (FTY-720), a sphingosine-1-phosphate receptor modulator, is the first US Food and Drug Administration (FDA)–approved oral agent for the treatment of relapsing forms of multiple sclerosis (MS). Two recent phase III clinical studies (TRANSFORMS [Trial Assessing Injectable Interferon vs FTY720 Oral in RRMS] and FREEDOMS [FTY720 Research Evaluating Effects of Daily Oral Therapy in MS]) demonstrated a significant reduction in the annualized relapse rate in patients with relapsing-remitting MS, compared to once weekly interferon β-1a and placebo. Macular edema was a prominent adverse event reported in these and prior studies of fingolimod. Thirteen of 2,564 (0.5%) patients treated with fingolimod in FREEDOMS and TRANSFORMS developed macular edema. Fingolimod-associated macular edema (FAME) appears to be dose-dependent (observed in only 2 patients taking the FDA-approved 0.5 mg dose) and typically resolves upon cessation of therapy. Although a relatively common condition in ophthalmology, most neurologists have not encountered macular edema in clinical practice. The purpose of this review is to educate the neurologist on the etiology, clinical manifestations, diagnostic modalities, and treatment approaches in patients with FAME. We also discuss the use of fingolimod in patients with uveitis and diabetes mellitus, highlight the guidelines for surveillance ophthalmic examination, and outline the key distinguishing features between FAME and optic neuritis.Keywords
This publication has 33 references indexed in Scilit:
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Regulation of vascular permeability by sphingosine 1-phosphateMicrovascular Research, 2009
- Activation of Sphingosine Kinase-1 Reverses the Increase in Lung Vascular Permeability Through Sphingosine-1-Phosphate Receptor Signaling in Endothelial CellsCirculation Research, 2008
- Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidenedionesDiabetic Medicine, 2008
- Acute Inflammatory Demyelinating Optic NeuritisThe Neurologist, 2008
- Randomized Controlled Trial of FTY720 Versus MMF in De Novo Renal TransplantationTransplantation, 2006
- Pulmonary Endothelial Cell Barrier Enhancement by Sphingosine 1-PhosphateJournal of Biological Chemistry, 2004
- Studies on the permeability of the blood-retinal barrier. I. On the existence, development, and site of a blood-retinal barrier.British Journal of Ophthalmology, 1966
- Pericytes in diabetic retinopathy.British Journal of Ophthalmology, 1966